Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
Synthetic antigen for the detection of AIDS-related disease Patent #: 4629783
ApplicationNo. 06/707066 filed on 03/01/1985
US Classes:435/5, Involving virus or bacteriophage435/180, Carrier is synthetic polymer435/805, TEST PAPERS435/974, AIDS RELATED TEST436/518, INVOLVING AN INSOLUBLE CARRIER FOR IMMOBILIZING IMMUNOCHEMICALS436/528, Carrier is organic436/531, Carrier is synthetic resin436/811, TEST FOR NAMED DISEASE, BODY CONDITION OR ORGAN FUNCTION530/324, 25 or more amino acid residues in defined sequence930/10, PEPTIDE OR PROTEIN SEQUENCE930/221Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related
ExaminersPrimary: Nucker, Christine M.
Attorney, Agent or Firm
International ClassesC12Q 1/70 (20060101)
C07K 14/005 (20060101)
C07K 14/16 (20060101)
A61K 38/00 (20060101)
AbstractGene segments of human T cell lymphotropic virus type III (HTLV-III) were expressed in E. coli as peptides that are reactive with sera from patients with acquired immune deficiency syndrome (AIDS). Among recombinant peptides one designated HTLV-III polypeptide 121, contained 85 amino acid residues encoded by a gene segment in the env-lor region of the HTLV-III genome. The polypeptide is strongly reactive with AIDS patient sera. The peptide produced and purified as a fusion protein on a large scale. Solid phase immunoassays employing this recombinant peptide as an immunoabsorbent can reliably and reproducibly detect antibodies in sera of patients with HTLV-III infection. In two representative serum panels, the assay detected the presence of antibodies in 120 of 121 sera from patients with AIDS or AIDS-related complex (ARC), and only in 1 of 92 normal controls. Based upon HTLV-III polypeptide 121 as immunoreactive agent, sensitive and specific immunoassays for HTLV-III infection have been developed.